Expression of cyclin dependent kinase inhibitor p21(waf1/cip1) in premalignant and malignant oral lesions: Relationship with p53 status

Oral Oncology

Volumn 34, Issue 5, 1998, Pages 353-360

  Agarwal, S ^a   Mathur, M ^a   Shukla, N K ^b   Ralhan, R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETEL EXTRACT; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; DYSPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TOBACCO;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; ODONTODYSPLASIA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032167413     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(98)00021-9     Document Type: Article

References (30)

1. Daftary DK, Murty PR, Bhonsle RR, Gupta PC, Mehra FS, Pindborg JJ. Risk factors and risk markers for oral cancer in high risk areas of the world. In: Johnson NW, editor. Oral Cancer: The Detection of Patients and Lesions at Risk, Cambridge: Cambridge University Press 1991. pp. 29-63.
2. Gupta PC, Mehta FS, Pinborg JJ, Aghi MB, Bhousk RB, Murti PR. An educational intervention study for tobacco chewing and smoking habits among Indian villagers. In: Hisamichi AM, Tominaga S, editors. Smoking and Health. Amsterdam: Excerpta Medica. 1981, p. 623.
3. Hect SS, Hoffman D. N-nitroso compounds and tobacco induced cancers in man. IARC Scientific Publication. 105:1991;54-61.
4. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
5. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science. 267:1995;1022-1024.
6. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabiel GJ. The p21 cyclin dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Medcine. 1:1995;1052-1056.
7. El-Deiry WS, Harper JW, O'Connor PM, et al. WAFI/CIPI is induced in p53-mediated G1 arrest and apoptosis. Cancer Research. 54:1994;1169-1174.
8. waf1/cip1 expression in the absence of p53. Oncogene. 9:1994;3397-3406.
9. Noda A, Ning Y, Benable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Experimental Cell Research. 211:1994;90-98.
10. Shiohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
11. Bhatia K, Fan S, Sprangler G, et al. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's Lymphoma. Cancer Research. 55:1995;1431-1435.
12. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell. 75:1993;817-825.
13. Liu Y, Martindale JL, Gorospe M, Holbrook NJ. Regulation of p21 expression through mitogen-activated protein kinase signalling pathway. Cancer Research. 56:1996;31-35.
14. Zeng YX, El-Deiry WS. Regulation of p2l/WAF1/CIP1 expression by p53-independent pathways. Oncogene. 12:1996;1557-1564.
15. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAFI/CIPI by a p53-independent pathway. Cancer Research. 54:1994;3391-3395.
16. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long term follow-up. Clin Cancer Res. 2:1996;1591-1599.
17. Johnson EA, Davidson AC, Hostetter RB, Cook TL, Thomas EM, Quinlan DC. The expression of Waf1 in node-negative infiltrating ductal breast carcinoma. Proc Am Assoc Cancer Res. 37:1996;569.
18. Kaur J, Srivastava A, Ralhan R. Overexpression of p53 protein in betel and tobacco related human oral dysplasia and squamous cell carcinoma in India. International Journal of Cancer. 58:1994;340-345.
19. waf1/cip1 expression in normal and neoplastic tissues. Cancer Research. 55:1995;2910-2919.
20. Parker SB, Eichele G, Zhang P, et al. p53-independent expression of p21/CIP1 in muscle and other terminally differentiated cells. Science. 267:1995;1024-1027.
21. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by myoD. Science. 267:1995;1018-1021.
22. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. British Journal of Cancer. 74:1996;208-215.
23. Doglioni C, Pelosio P, Laurino L, Macri E, Barbareschi M. p21/WAF1/CIP1 expression in normal mucosa, adenomas and adenocarcinomas of the colon: its relationship with differentiation. Journal of Pathology. 179:1996;248-253.
24. Ozcelik H, Mousses S, Andrulis IL. Low levels of expression of an inhibition of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res. 1:1995;907-912.
25. Tahara E. Molecular biology of gastric cancer. World Journal of Surgery. 19:1995;484-490.
26. Vidal MJ, Loganzo F, de Oliveira AR, Hayward NK, Albino AP. Mutations and defective expression of the WAF1/p21 tumor-suppressor gene in malignant melanomas. Melanoma Research. 5:1995;243-450.
27. Digiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. American Journal of Pathology. 147:1995;884-888.
28. Zhang W, Grasso L, McClain CD, et al. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompaning monocyte/macrophage differentiation. Cancer Research. 55:1995;668-674.
29. Marchetti A, Buttitta F, Pellegrini S, Lori A, Bertacca G, Bevi-Lacqua G. Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinomas: a polymorphism at codon. International Journal of Oncology. 6:1995;187-189.
30. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor B induces the cyclin dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 92:1995;5545-5549.